Apellis Provides Update on Review of Rare Safety Events with SYFOVRE® (pegcetacoplan injection) for Geographic Atrophy
29 juil. 2023 14h52 HE
|
Apellis Pharmaceuticals, Inc.
No indication that drug product or manufacturing issues contributed to rare events of retinal vasculitisConfirmed seven total events of non-occlusive/occlusive retinal vasculitis since launch; more...
Apellis Pharmaceuticals to Host Conference Call on July 31, 2023, to Discuss Second Quarter 2023 Financial Results
24 juil. 2023 09h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., July 24, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Announces Seven Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
10 juil. 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
New 30-month data from the GALE long-term extension study of SYFOVRE® (pegcetacoplan injection) to be presented WALTHAM, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc....
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 juil. 2023 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM Mass., July 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
07 juin 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., June 07, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06 juin 2023 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., June 06, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Reports Top-Line Results from Phase 2 MERIDIAN Study in ALS
25 mai 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Phase 2 MERIDIAN study investigating systemic pegcetacoplan for the treatment...
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 mai 2023 16h05 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., May 05, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company approved...
Apellis Pharmaceuticals Reports First Quarter 2023 Financial Results
04 mai 2023 16h05 HE
|
Apellis Pharmaceuticals, Inc.
Generated U.S. net product revenues of $18.4 million for SYFOVRE™ (pegcetacoplan injection) and $20.4 million for EMPAVELI® (pegcetacoplan) SYFOVRE launched in the U.S. as the first and only treatment...
Apellis Pharmaceuticals to Present at the Bank of America Securities 2023 Healthcare Conference
03 mai 2023 07h00 HE
|
Apellis Pharmaceuticals, Inc.
WALTHAM, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will...